# Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

> **NCT01925573** · NA · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 7 (actual)

## Conditions studied

- RECURRENT GLIOBLASTOMA
- Brain Tumor

## Interventions

- **DEVICE:** Optune(NOVOTTF-100A)

## Key facts

- **NCT ID:** NCT01925573
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2022-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01925573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01925573, "Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01925573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*